<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	Methods, paragraph 1,2 and 8	
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.		No
Provide accession number in repository OR		cell
supplier name, catalog number, clone number,		mate rials
OR RRID		TIdis
Primary cultures: Provide species, strain, sex of		No
origin, genetic modification status.		cell
		mate
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		no
genetic modification status. Provide accession		Expe rime
number in repository OR supplier name, catalog		ntal
number, clone number, OR RRID		anim
Animal observed in or captured from the		no
field: Provide species, sex and age where		Expe
possible		rime ntal
Model organisms: Provide Accession number		no
in repository (where relevant) OR RRID		Expe
		,
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a No
Plants: provide species and strain, unique accession		Plant
number if available, and source (including location		s and
for collected wild specimens)		micro bes
Microbes: provide species and strain, unique		No Plant
accession number if available, and source		s and
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Ethical Statement	, a
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent		Infor
obtained from study participants.		med
Report on age and sex for all study participants.	Methods, paragraph 1	

<u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration		No clini
number OR cite DOI in manuscript.		cal trial
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-		no Lab
by-step protocols are available.		ora
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	Methods, paragraph 1	
done, or if they were not carried out.		
Sample size determination	Methods, paragraph 1	
Randomisation	Methods, paragraph 1	
Blinding	Methods, paragraph 1	
Inclusion/exclusion criteria	Methods, paragraph 1	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was		No
replicated in laboratory		in- lab
Define whether data describe technical or biological		No
replicates		in- lab
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of		No
authority granting ethics approval (IRB or equivalent		Eth
committee(s), provide reference number for		ics
approval.		
Studies involving experimental animals: State details of authority granting ethics approval (IRB or		No
equivalent committee(s), provide reference number		Eth
for approval.		ics
Studies involving specimen and field samples: State if		No
relevant permits obtained, provide details of		Eth
authority approving study; if none were required,		ics
explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,	res (indicate where provided, section, paragraph)	N
in stady is subject to data use rescarch of concern,		IN
state the authority granting approval and reference		0

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	(No
excluded, and whether the criteria for exclusion were		ex
determined and specified in advance.		clu
		de
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Methods, paragraph 8	
16515.		
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	Data sharing statement	
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession	Data sharing statement	
number in repository or DOI or URL.		
If publicly available data are reused, provide	Data sharing statement	
accession number in repository or DOI or URL, where		
possible.		
Code Availability	Ves (indicate where provided, as tion (non-month)	
	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		No
for replicating the main findings of the study:		cod
State whether the code or software is available.		No cod
If code is publicly available, provide accession		No cod
number in repository, or DOI or URL.		cod

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of	Footnote	
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: http://dx.doi.org/10.21037/atm-21-1162